Hers Medical Leadership and Credentials: An Independent Review

What Hers Is and Who It Serves

Hers is a subscription-based telehealth company built exclusively for women. It sits under the Hims & Hers Health umbrella, a publicly traded company (NYSE: HIMS) that operates separate consumer brands for men (Hims) and women (Hers). The women-only Hers platform covers weight management with GLP-1 receptor agonists, menopausal hormone therapy, mental health prescriptions, female pattern hair loss, and medical-grade skincare.

The target reader for this review is you: a woman weighing whether Hers is a clinically credible place to get ongoing prescriptions, not just a convenient one. Those are different questions.

Who Owns and Operates the Clinical Side

Hims & Hers Health does not itself prescribe. Like most D2C telehealth companies operating across state lines, it contracts with affiliated medical professional corporations (PCs) that employ or contract with licensed physicians, NPs, and PAs in each state. The exact PC name and its medical director are not prominently disclosed on the Hers consumer website as of July 2025.

This matters. When a telehealth platform does not name its supervising physicians or medical director on its public-facing site, you cannot independently verify their board certifications, disciplinary history, or specialty training through a state licensing board lookup. Every state medical board in the US maintains a public license-verification tool. The Federation of State Medical Boards maintains a central DocInfo directory where you can check any licensed physician by name. If Hers has not given you a prescriber's name, start there once you receive your intake confirmation.

The Hims & Hers Chief Medical Officer

Hims & Hers Health named Patrick Carroll, MD as its Chief Medical Officer. Dr. Carroll is a family medicine physician. His appointment and background have been covered in Hims & Hers investor filings. The company has not publicly named a separate CMO or Medical Director specifically for the Hers women's-health division. Whether the women's clinical protocols are overseen by a physician with subspecialty training in obstetrics-gynecology, reproductive endocrinology, or menopause medicine (such as a NAMS Certified Menopause Practitioner) is not confirmed in public documentation as of mid-2025.

The absence of a named women's health subspecialist in a visible leadership role is a meaningful gap for a platform prescribing estradiol patches, progesterone, and GLP-1 agents to women across reproductive, perimenopausal, and post-menopausal life stages. This does not mean the protocols are wrong, but it does mean you cannot verify the credential chain without contacting Hers directly and asking for your prescriber's license number and specialty.

Is Hers Legit? Licensing, Regulatory Standing, and Complaint Data

Hers operates legally as a telehealth platform in the states where its affiliated providers hold licenses. That is the baseline legal minimum. "Legit" for a telehealth company means more than a business license.

LegitScript Certification

LegitScript is the gold-standard third-party verification body for online pharmacies and telehealth prescription services. Its certification confirms that a platform follows applicable laws, employs licensed practitioners, and dispenses from licensed pharmacies. As of July 2025, Hers does not appear in LegitScript's certified telehealth merchant database. The absence of LegitScript certification does not mean a platform is operating illegally, but it does mean no independent third party has audited its prescribing and dispensing practices.

BBB Profile and Complaints

Hims & Hers Health is not accredited by the Better Business Bureau. The BBB profile for Hims & Hers shows a pattern of complaints, with the most common themes being:

• Billing and subscription cancellation difficulties
• Delays in prescription fulfillment, particularly for compounded GLP-1 medications
• Poor customer service responsiveness when medical questions arise
• Difficulty reaching a live provider after the initial intake visit

The BBB complaint volume for a company Hers's size is not unusual, but the billing and cancellation complaints are a consistent pattern worth noting before you enter a subscription.

FDA and Compounding Pharmacy Concerns

Hers, like many weight-loss telehealth platforms, has offered compounded semaglutide and tirzepatide through 503A and 503B compounding pharmacies during the period of Ozempic and Wegovy shortage designations. The FDA issued multiple warnings between 2023 and 2025 about compounded semaglutide, including concerns about dosing errors from salt-form semaglutide products and inadequate labeling. In February 2025, the FDA removed semaglutide from its shortage list, which under federal law triggers compounding restrictions. Women who received compounded semaglutide through Hers should confirm with their prescriber whether they have transitioned to an FDA-approved branded product and whether their current compound is from a pharmacy that remains in legal compliance.

The FDA's current guidance on compounded semaglutide is the definitive source for this.

What Hers Prescribes: A Women's-Health Clinical Overview

Understanding what Hers offers requires looking at each treatment category through a women's-health lens: what life stage it serves, what the clinical evidence says, and where sex-specific physiology changes the risk or dose calculation.

GLP-1 Weight Management

Hers prescribes semaglutide (branded Wegovy at 2.4 mg weekly for weight; Ozempic at up to 2 mg weekly for diabetes) and, in some states, tirzepatide (Zepbound). The STEP 1 trial demonstrated that semaglutide 2.4 mg weekly produced a mean 14.9% body weight reduction over 68 weeks in adults with obesity or overweight with a weight-related comorbidity, compared with 2.4% in the placebo group.

Women-specific physiology matters here. Women respond to GLP-1 agents with slightly greater nausea rates than men in clinical trials, partly because gastric emptying is already slower in women, a difference that is amplified by progesterone during the luteal phase of the menstrual cycle. A 2023 pharmacokinetic analysis found that female sex is associated with higher GLP-1 receptor agonist plasma exposure at equivalent doses, which may explain the higher nausea burden and could support starting at the lowest dose with a slower titration for many women.

PCOS and weight: Women with polycystic ovary syndrome have insulin resistance as a core pathophysiologic driver. GLP-1 agents reduce fasting insulin and improve menstrual regularity in women with PCOS, though the data are from small trials. A 2022 systematic review in Fertility & Sterility found that liraglutide improved menstrual frequency and reduced androgen levels in women with PCOS and obesity. Whether semaglutide produces the same magnitude of benefit is not yet established in adequately powered trials specific to PCOS.

Perimenopause and post-menopause: Estrogen decline shifts fat distribution toward the abdomen and increases insulin resistance. GLP-1 agents appear to reduce visceral adiposity, which may carry cardiovascular benefit for post-menopausal women who carry a disproportionate share of cardiovascular disease burden. The SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, but the female subgroup analysis has not been separately published in sufficient detail to draw firm sex-specific conclusions.

Menopausal Hormone Therapy

Hers offers estradiol and progesterone in patch, pill, and gel formulations for perimenopausal and post-menopausal symptom management. The Menopause Society 2023 position statement supports hormone therapy as the most effective treatment for vasomotor symptoms and acknowledges that for healthy women under 60 or within 10 years of menopause onset, the benefits of HT generally outweigh the risks.

A key issue with telehealth HRT prescribing is baseline evaluation. Standard of care before initiating HRT includes a personal and family history of hormone-sensitive cancers, cardiovascular risk assessment, and in some cases pelvic evaluation for uterine status (because unopposed estrogen increases endometrial cancer risk, and women with an intact uterus require progestogen). Whether Hers's asynchronous intake process captures sufficient data for this risk stratification is not publicly documented.

Mental Health Prescriptions

Hers prescribes SSRIs, SNRIs, and non-stimulant anti-anxiety medications. Women are diagnosed with depression and anxiety at approximately twice the rate of men across reproductive years, and hormonal fluctuations across the menstrual cycle, postpartum period, and menopause transition substantially influence symptom presentation and medication response. A 2022 review in JAMA Psychiatry documented that women metabolize several SSRIs differently than men, with relevant implications for dose and side-effect burden.

Hers does not appear to offer psychiatry-level care for complex diagnoses. If you have a history of bipolar disorder, psychosis, or treatment-resistant depression, a platform offering async or brief synchronous visits with a general prescriber is not adequate.

Female Pattern Hair Loss

Hers offers minoxidil (topical 2% and 5%, as well as oral low-dose), finasteride, and spironolactone for androgenetic alopecia. FDA approval for topical minoxidil 2% in women dates to 1991. Oral minoxidil at 0.25 to 2.5 mg daily is used off-label.

Sex-specific note: Finasteride is FDA-approved only in men for androgenetic alopecia. Its use in women is off-label and, critically, absolutely contraindicated in pregnancy due to risk of feminization of a male fetus. See the pregnancy section below.

Pregnancy, Lactation, and Contraception: What Hers Prescribes and What You Need to Know

This section applies to any woman of reproductive age using Hers services. Several medications available through the platform carry serious pregnancy risks.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are contraindicated in pregnancy. FDA prescribing information for Wegovy states that the drug should be discontinued at least two months before a planned pregnancy due to its long half-life and the potential for fetal harm observed in animal reproductive studies. Women who become pregnant while taking semaglutide should stop the medication immediately and contact their obstetric provider. GLP-1 agents are also not recommended during breastfeeding due to unknown transfer into human milk and potential effects on the nursing infant's developing GI tract.

Women of reproductive age who are prescribed GLP-1 agents should use reliable contraception. GLP-1 agents may also alter the absorption of oral contraceptive pills by slowing gastric emptying, which could reduce OCP efficacy. A drug interaction study found reduced Cmax of ethinyl estradiol with concurrent GLP-1 use, supporting use of a non-oral contraceptive method or backup contraception for women on both drugs.

Finasteride

Finasteride is a known teratogen in male fetuses. FDA labeling for finasteride states that women who are or may become pregnant must not handle crushed or broken finasteride tablets and must not take it. Women of reproductive age prescribed finasteride off-label for hair loss must use effective contraception for the duration of treatment and ideally for one month after discontinuation. This risk requires explicit informed consent, and a telehealth platform prescribing finasteride to women should be documenting contraceptive status.

Spironolactone

Spironolactone is commonly used off-label for hormonal acne and hair loss in women. Animal studies suggest antiandrogenic effects that could affect male fetal development, and the drug is generally avoided in pregnancy. ACOG guidance recommends that women on spironolactone for non-cardiac indications use reliable contraception.

SSRIs/SNRIs During Pregnancy and Postpartum

If you are prescribed an SSRI through Hers and subsequently become pregnant, do not stop abruptly without clinician guidance. Untreated perinatal depression carries significant maternal and fetal risk. A 2023 ACOG practice bulletin supports continuing antidepressants in pregnancy when benefits outweigh risks, with individualized decision-making. Transition of care from a telehealth prescriber to an OB or perinatal psychiatrist is strongly recommended during pregnancy.

Who Hers Is Right For (and Who It Is Not)

Not every telehealth platform fits every woman. Here is a life-stage breakdown.

Reproductive Years (18 to 44)

Hers may work well if you need a refill of a stable SSRI, a minoxidil prescription for early androgenetic alopecia, or evaluation for GLP-1 therapy for obesity or PCOS-related metabolic disease. You need a reliable contraceptive plan in place before starting finasteride, spironolactone, or GLP-1 agents. The platform is not adequate for managing complex PCOS with fertility goals, for postpartum mental health crises, or for endometriosis requiring surgical evaluation.

Perimenopause (Typically 40 to 52)

Hers could be a starting point for vasomotor symptom management with estradiol and progesterone if you are otherwise healthy, have no personal history of breast cancer, and have a relatively straightforward symptom picture. A platform that does not conduct a full cardiovascular and cancer risk assessment before prescribing is a meaningful gap for women approaching menopause with complex histories. The Menopause Society recommends individualized risk assessment before initiating HRT.

Post-Menopause (52 and older)

GLP-1 agents for post-menopausal metabolic disease and continuation of established HRT are reasonable use cases. New initiation of HRT more than 10 years after menopause or after age 60 carries a different risk profile that requires in-person evaluation by a menopause specialist, not an async telehealth visit.

Who Should Not Use Hers as a Primary Care Source

• Women with active or prior hormone-sensitive breast or uterine cancer
• Women with a current or planned pregnancy
• Women with bipolar disorder, psychosis, or a recent psychiatric hospitalization
• Women with complex fertility goals requiring specialist care
• Women on multiple medications with known interactions (e.g., anticoagulants plus SSRIs)

How Hers Compares on Transparency

A useful framework for evaluating any telehealth platform is what we call the Credential Transparency Ladder: four public disclosures that distinguish credible platforms from opaque ones.

1. Named Medical Director with specialty credential and state license number posted publicly.
2. Named prescriber at point of prescription, with license verification link.
3. LegitScript or equivalent third-party pharmacy certification.
4. Explicit informed consent documentation for teratogenic medications, available to the patient.

As of mid-2025, Hers publicly meets rung 2 (you receive your prescriber's name on your prescription) but does not clearly meet rungs 1, 3, or 4 based on publicly available information. That does not make it illegal. It does mean you should do the verification work yourself: look up your prescriber's license on your state medical board website after your first visit, ask Hers directly which compounding pharmacy fills your GLP-1 prescription and whether it is a 503B outsourcing facility, and request written documentation of the informed consent process for any teratogenic drug.

How to Verify Your Hers Prescriber Independently

After any telehealth visit, you will receive a prescription or a summary that names your provider. With that name in hand:

1. Visit your state's medical board website (find it via the Federation of State Medical Boards DocInfo tool).
2. Search by the provider's name. Confirm an active, unrestricted license.
3. Check for any disciplinary actions or board sanctions.
4. If the provider is an NP or PA, search the relevant nursing or pharmacy board.

This takes four minutes. It is the single most useful step you can take after signing up for any telehealth service.

Hers Complaints: Patterns Worth Knowing

The most consistent complaint patterns visible across BBB filings, Trustpilot, and Reddit's r/Ozempic and r/FemaleHairLoss communities include:

• Subscription cancellation: Multiple users report difficulty canceling recurring charges, sometimes requiring credit card disputes.
• Compounded GLP-1 delays: During the 2023 to 2024 shortage period, compounded semaglutide shipment delays of 4 to 8 weeks were reported. Women who had titrated up to effective doses and then experienced a supply gap reported significant weight regain consistent with what is documented in clinical literature. The STEP 4 withdrawal trial showed that participants who stopped semaglutide regained approximately two-thirds of lost weight within one year.
• Async-only follow-up: Some women report that after the initial intake, follow-up is handled entirely through messaging, with no real-time clinical contact available for side-effect management.
• Formulary shifts: Several users report their compounded semaglutide was discontinued with short notice as FDA shortage status changed, without adequate transition planning to branded alternatives.

None of these complaints indicate illegal operation. They do indicate a service model optimized for patient acquisition more than ongoing clinical management, which is a pattern across the D2C telehealth sector, not unique to Hers.